{"filing":{"accession_number":"0001193125-26-257760","cik":"0001819133","ticker":"TNGX","company_name":"Tango Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"d149262d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526257760/d149262d8k.htm"},"events":[{"id":6839,"run_id":5990,"accession_number":"0001193125-26-257760","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a Form 8-K Item 5.07 disclosure of shareholder meeting results. The filing reports the final voting outcomes for three proposals at the June 4, 2026 annual meeting: election of two Class II directors (Malte Peters, M.D. and Mace Rothenberg, M.D.), ratification of PricewaterhouseCoopers, LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure includes vote tallies, quorum confirmation (90.96% attendance), and context regarding a prior director resignation. This is a material event as it reflects stockholder decisions on board composition and corporate governance matters.","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4373,"accession_number":"0001193125-26-257760","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a Form 8-K Item 5.07 disclosure of shareholder meeting results. The filing reports the final voting outcomes for three proposals at the June 4, 2026 annual meeting: election of two Class II directors (Malte Peters, M.D. and Mace Rothenberg, M.D.), ratification of PricewaterhouseCoopers, LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure includes vote tallies, quorum confirmation (90.96% attendance), and context regarding a prior director resignation. This is a material event as it reflects stockholder decisions on board composition and corporate governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:00:10.055200+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4373,"accession_number":"0001193125-26-257760","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a Form 8-K Item 5.07 disclosure of shareholder meeting results. The filing reports the final voting outcomes for three proposals at the June 4, 2026 annual meeting: election of two Class II directors (Malte Peters, M.D. and Mace Rothenberg, M.D.), ratification of PricewaterhouseCoopers, LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure includes vote tallies, quorum confirmation (90.96% attendance), and context regarding a prior director resignation. This is a material event as it reflects stockholder decisions on board composition and corporate governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:00:10.055200+00:00","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-06-04"}]}